# of Displayed Technologies: 10 / 14

Applied Category Filter (Click To Remove): Healthcare Portfolios


Categories

Novel Natural Product Derivatives Targeting Chronic Diseases
TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity
The Need Metabolic disorders such as type 2 diabetes are a major health concern that have impacted hundreds of millions of adults worldwide. Current pharmaceutical therapies for type 2 diabetes have been associated with adverse reactions including weight gain and increased risk of infection, liver …
  • College: College of Pharmacy
  • Inventors: Carcache de Blanco, Esperanza; Anaya Eugenio, Gerardo David; Eggers, Nicole
  • Licensing Officer: Ezzell, Janel

Analogues of the Epipolythiodioxopiperazine Alkaloids
TS-047118 — Analogues of verticillin which have more useful drug-like properties than the verticillin parent compounds alone, including increased solubility, absorption, and stability, all while maintaining similar anticancer potency to the original compounds.
Verticillins, which are epipolythiodioxopiperazine (ETP) alkaloids, have shown promising anticancer qualities; these fungal metabolites have exhibited high potency against a variety of tumor cell types, with IC50 values typically in the 10-500 nanomolar range. However, these compounds suffer from …
  • College: College of Pharmacy
  • Inventors: Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Ezzell, Janel

Adoptive Transfer of Engineered Macrophages
TS-045881 — The Need Cell therapies have received recent approvals for immunomodulatory indications. Immuno-activating chimeric antigen receptor (CAR)–T cells have been developed for cancers, whereas immunosuppressive mesenchymal stromal cells (MSCs) have been approved for inflammatory bowel disease and …
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Hou, Xucheng; Zhang, Xinfu
  • Licensing Officer: Ezzell, Janel

Composition and method of lipid nanoparticles carrying oligonucleotides
TS-043629 — Novel lipid nanoparticles used for carrying antisense oligonucleotides with improved targeting for cancer treatment
Lung cancer is the leading cause of cancer related deaths in the US with approximately 150,000 deaths in 2017. Currently, mildly ineffective chemotherapeutics ripe with adverse side effects are the standard treatment. Antisense oligonucleotides (ASOs) are able to selectively modulate expression of
  • College: College of Pharmacy
  • Inventors: Lee, Robert; Cheng, Xinwei "Evan"
  • Licensing Officer: Ezzell, Janel

Self-assembled 3D RNA Cage Nanoparticles with Precise Shape and Size for Applications in Medical Sciences, Materials Sciences, Engineering and Nanotechnology
TS-039545 — Self-assembling, highly stable RNA cages amenable to custom functionalization and cargo delivery
One of the primary challenges in therapeutic development is cheap, efficient, and safe drug delivery to specific target tissues. To better target specific tissues, RNA nanotechnology has been progressively applied to generate predefined architectures via self-assembly of modular building blocks. N…
  • College: College of Pharmacy
  • Inventors: Guo, Peixuan; Jasinski, Daniel; Khisamutdinov, Emil; Li, Hui; Xu, Congcong
  • Licensing Officer: Ezzell, Janel

Method for Large scale production of RNA or RNA nanoparticles via the combination of rolling circle transcription and ribozyme processing.
TS-037876 — A new method to produce RNA and RNA nanoparticles by using rolling circle transcription to produce RNA on a large scale.
Since RNA interference was first described and utilized in 1998, the field has been expanding at an immense pace. Many types of therapeutics have been developed using synthetically constructed RNA interference nanotechnology, including work in the fields of cancer, immune therapy, and other human …
  • College: College of Pharmacy
  • Inventors: Guo, Peixuan; Jasinski, Daniel
  • Licensing Officer: Ezzell, Janel

Amino Esters and Uses Thereof
TS-037840 — Amino esters nanomaterials for gene therapy and drug delivery.
The Need The efficient delivery of mRNA is a key challenge for the application of mRNA therapeutics. Despite promising data from ongoing clinical trials for the treatment of cancer vaccines, the clinical use of mRNA requires the discovery and development of safer and more effective delivery systems…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Luo, Xiao; Zhang, Xinfu
  • Licensing Officer: Ezzell, Janel

Phyllanthusmin and acutissimalignan A compound derivatives for anticancer and immunostimulation
TS-037721 — A group of potential antitumor arylnapthalene lactone derivatives, which may be developed as novel anticancer and immunostimulant agents.
Natural products and semi-synthetic derivatives derived from them have been used for anticancer drugs or drug leads for many years. However, side-effects such as myelosuppression and secondary leukemia have been reported. Furthermore, these natural products can be difficult to use for targeting sp…
  • College: College of Pharmacy
  • Inventors: Kinghorn, Alan "Dr. A. Douglas Kinghorn"; Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Ezzell, Janel

STAT3 Inhibitors and Their Anti-Cancer Usage
TS-037671 — Novel non-peptidomimetic molecules for use as anti-cancer inhibitors of signal transducer and activator of transcription 3.
The search for more potent drug delivery candidates for cancer therapy remains a challenge within the medical community. Efforts to target cancer at the genetic level have led to numerous discoveries, including the role that constitutive activation of signal transducer and activator of transcripti…
  • College: College of Pharmacy
  • Inventors: Li, Chenglong; Lin, Jiayuh; Yu, Wenying
  • Licensing Officer: Ezzell, Janel

Development of STAT3 dimerization inhibitors for cancers
TS-037569 — The constant activation of Signal Transducer and Activator of Transcription 3 (STAT3) is frequently detected in many cancer patients with advanced diseases. About 80% of all cancers overexpress STAT3, including solid tumors, lymphoma, and leukemia. Constant activation of STAT3 activities in nonmal…
  • College: College of Pharmacy
  • Inventors: Li, Pui-Kai "Tom"; Li, Chenglong; Lin, Jiayuh
  • Licensing Officer: Ezzell, Janel

Show More Technologies

Loading icon